Growth and Strategic Expansions in 2024 With Over $3.7 Million In Assets

MELBOURNE, Fla., April 16, 2024 /PRNewswire/ -- Branded Legacy, Inc, (OTC.PK: BLEG) a leading provider of innovative wellness products, is pleased to announce a net income for the fiscal year 2023 of $3,825,527, a substantial increase driven by the strategic retirement of over 2.4 billion shares. As they forge into 2024, the company has signed multiple on-going white label contracts, poised to further enhance our revenue and profitability for the coming year and beyond.

"2023 was a year of substantial growth and strategic repositioning for Branded Legacy. As we continue to expand and innovate, our focus remains steadfast on leveraging our core strengths in biotechnology to improve human health globally," said David Oswald, CEO of Branded Legacy.

In a remarkable development, Branded Legacy has welcomed Dr. Mark T. Hamann, the Endowed Chair of Drug Discovery and Biomedical Sciences at the MUSC College of Pharmacy, to guide its forthcoming clinical trials. This follows the Company's recent strategic acquisition of Sycamore BioPharma, Inc., a distinguished developer of plant-based pharmaceuticals. This acquisition not only secured assets exceeding $2 million but also integrates key personnel vital for advancing their clinical trials.

The company's recent strategic endeavors include the acquisition of several companies, bringing over $3.7 million worth of advanced scientific equipment and inventory. This expansion has necessitated a move to a larger, state-of-the-art facility in Melbourne, FL, to accommodate their growing operations and align with their commitment to biotechnological advancement and improving human health.

The Company's total assets have seen an astronomical increase to $3,787,215.00, the majority in 2024, marking a 1,412% increase compared to the end of Q3. The newly acquired laboratory and packaging equipment significantly bolsters capacities in R&D, production, and packaging.

The extensive equipment range acquired includes High-Performance Liquid Chromatography and Gas Chromatography systems, various centrifuges, vacuum ovens, an irradiating flow hood, incubators, and more. This arsenal of advanced tools empowers the Company to conduct precise chemical analyses, foster controlled research environments, and enhance product development efficiency across various stages.

Furthering its expansion strategy, Branded Legacy, Inc. proudly announced its acquisition of MariJ Pharmaceuticals, Inc. This deal significantly broadens their asset base and intellectual property portfolio, integrating a compounding pharmacy license, state-of-the-art supercritical CO2 extraction units, and a fleet of specialized vehicles designed for mobile extraction and refinement.